Effect of dipyridamole treatment on proteinuria in pediatric renal disease.
The effect of dipyridamole on proteinuria was studied in 60 children with various renal diseases. A significant decrease in 24-hour urine protein excretion was observed within a few months after treatment in 32 (53%) of the patients with minimal or moderate mesangial proliferation. The effect was reproducible and parallelled by a reduction in plasma levels of beta-thromboglobulin. Renal function in patients significantly improved with the therapeutical effect. The appropriate dosage was 4-10 mg/kg daily and no serious toxicity was seen despite large dosage and even in long-term application. The data suggest that dipyridamole treatment appears safe and has a beneficial effect on proteinuria dependent on its effect on platelets in renal disease.
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D004176:Dipyridamole / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000503:physiopathology; D005922:Glomerulonephritis, IGA / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D011695:IgA Vasculitis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D011507:Proteinuria
D004176:Dipyridamole